Free Trial
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Arrowhead Pharmaceuticals logo
$22.34 +0.55 (+2.52%)
Closing price 04:00 PM Eastern
Extended Trading
$22.28 -0.05 (-0.25%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Key Stats

Today's Range
$21.73
$22.75
50-Day Range
$14.71
$21.79
52-Week Range
$9.57
$27.34
Volume
2.48 million shs
Average Volume
1.96 million shs
Market Capitalization
$3.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.14
Consensus Rating
Buy

Company Overview

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

ARWR MarketRank™: 

Arrowhead Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 257th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Arrowhead Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($3.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arrowhead Pharmaceuticals is -17.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arrowhead Pharmaceuticals is -17.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arrowhead Pharmaceuticals has a P/B Ratio of 5.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.78% of the float of Arrowhead Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Arrowhead Pharmaceuticals has recently increased by 4.19%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Arrowhead Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.78% of the float of Arrowhead Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Arrowhead Pharmaceuticals has recently increased by 4.19%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Arrowhead Pharmaceuticals has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Arrowhead Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    Only 3 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $200,000.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of Arrowhead Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arrowhead Pharmaceuticals' insider trading history.
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARWR Stock News Headlines

Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $43.14
What is HC Wainwright's Forecast for ARWR FY2025 Earnings?
See More Headlines

ARWR Stock Analysis - Frequently Asked Questions

Arrowhead Pharmaceuticals' stock was trading at $18.80 at the start of the year. Since then, ARWR stock has increased by 18.7% and is now trading at $22.32.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Thursday, August, 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by $0.32. The biotechnology company earned $27.77 million during the quarter, compared to analyst estimates of $29.01 million.
Read the conference call transcript
.

Top institutional shareholders of Arrowhead Pharmaceuticals include State Street Corp (4.61%), Geode Capital Management LLC (2.16%), Marshall Wace LLP (1.56%) and Norges Bank (1.39%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, William D Waddill, Adeoye Y Olukotun, Hongbo Lu and Victoria Vakiener.
View institutional ownership trends
.

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARWR
CIK
879407
Employees
400
Year Founded
2001

Price Target and Rating

High Price Target
$80.00
Low Price Target
$17.00
Potential Upside/Downside
+93.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$599.49 million
Net Margins
N/A
Pretax Margin
-27.47%
Return on Equity
-40.91%
Return on Assets
-11.62%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
4.87
Quick Ratio
4.87

Sales & Book Value

Annual Sales
$3.55 million
Price / Sales
870.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.76 per share
Price / Book
5.94

Miscellaneous

Outstanding Shares
138,260,000
Free Float
132,313,000
Market Cap
$3.09 billion
Optionable
Optionable
Beta
0.94

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ARWR) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners